Evidence status: CURRENT PENNSYLVANIA PATIENT-ADVOCACY AND SAFETY GUIDANCE. Pennsylvania’s Department of Health maintains a Patient Advocacy Program specifically relevant to patients prescribed controlled substances and publishes safeguards against harmful misapplication of opioid guidance.

Patient Advocacy Program

The Department identifies the Patient Advocacy Program as a point of contact and resource coordinator for Pennsylvania patients who are prescribed controlled substances.

Displaced-patient concerns

The Department warns that abrupt loss of controlled-substance care can expose patients to severe withdrawal and can increase the risk that a patient turns to other sources, increasing overdose risk. Providers are encouraged to help displaced patients re-establish care quickly and safely.

Rapid tapering and sudden discontinuation

State treatment-agreement guidance warns that rapid tapering or abrupt cutoff in physically dependent patients can cause withdrawal, worsening pain, psychological distress, and overdose risk. It directs clinicians toward HHS and CDC tapering guidance rather than treating discontinuation as a purely administrative event.

Misapplication of guidelines

Pennsylvania has also warned prescribers about common misapplications of CDC and Pennsylvania opioid-prescribing guidelines and the PDMP system. The state’s position is that guidance should support individualized care rather than function as an inflexible dose or access rule.

Communication and stigma

Department materials recommend simple language, honest explanation of testing and discontinuation policies, and avoidance of mistrustful or accusatory treatment-agreement language that may stigmatize patients.

Why this belongs in the record

Act 112 imposes the agreement. Pennsylvania’s own patient-advocacy materials simultaneously recognize that agreement implementation, tapering, and care termination can cause harm if handled mechanically. Both layers belong in an accurate state record.

Sources

Reviewed: October 4, 2026.